Search Results

Contineum Therapeutics, Inc. (Nasdaq: CTNM) today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors.

Contineum Therapeutics, Inc. announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee.

Contineum Therapeutics, Inc. (Nasdaq: CTNM) today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024 in Miami.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications, announced the appointment of John Healy as General Counsel & Corporate Secretary.

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of NI&I indications, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Contineum Therapeutics, Inc. announced the pricing of its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share.

Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.